U.S. Health Secretary Robert F. Kennedy Jr. has proposed to Congress that clinical psychedelic therapies, including substances like MDMA and ibogaine, could receive approval within the next 12 months to treat conditions such as depression and trauma. This initiative follows recent setbacks at the Food and Drug Administration (FDA) regarding psychedelic treatments. Kennedy Jr. is supported by former Trump administration officials, including Rick Perry and Veterans Affairs Secretary Doug Collins, who have also expressed support for the advancement of psychedelic therapies. The push by Kennedy Jr. and his allies marks a notable political endorsement for the emerging field of psychedelic medicine, which remains under debate regarding its potential benefits and regulatory challenges.